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PREFACE 
  
 
 The exact cause of primary hypertension remains unknown but genetic, 
lifestyle and other environmental factors have been implicated in the pathogenesis of 
primary hypertension.  There is also a belief that a number of lifestyle diseases might 
have their origins in the foetus and that early intervention during fetal life or 
immediate postnatal life might modify the subsequent development of these diseases.  
This thesis documents a study examining the consequences of both intrauterine and 
extrauterine environmental modifications on the development of hypertension in 
spontaneously hypertensive rats (SHR), where the hypertension is genetic.  The study 
was conducted in four stages or phases and the layout of the thesis is as follows.  
 Chapter 1 provides a review of the literature on the subject of hypertension 
and oxidative stress, leading to the hypotheses and the objectives of this research.  
Chapter 2 describes the general materials and methods used in the four phases of the 
study.  Chapter 3 reports the first stage of the study examining the differences in 
blood pressure profile and the antioxidant system between SHR and their controls, 
the WKY rats.  Chapter 4 documents the second stage of the study where the effect 
of cross-fostering of offspring between SHR and WKY rats on blood pressure and 
renal antioxidant system was examined.  Chapter 5 reports the third stage of the 
study, which examined the effect of antenatal and postnatal melatonin 
supplementation on blood pressure and renal antioxidant system.  Chapter 6 
documents the fourth stage of the study where the effect of both antenatal and 
postnatal melatonin supplementation together with cross-fostering on the 
development of hypertension and renal antioxidant systems is examined. Chapter 7 
discusses the overall discoveries and summarises the important findings.  
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KESAN PELIHARAAN SILANG DAN PEMBERIAN MELATONIN KE 
ATAS PERKEMBANGAN HIPERTENSI DAN SISTEM 
ANTIOKSIDAN/OKSIDAN GINJAL DALAM TIKUS HIPERTENSI 
SPONTAN 
 
ABSTRAK 
 
 Pelbagai intervensi di awal hayat SHR telah dilakukan dalam percubaan 
untuk memprogram semula profil peningkatan tekanan darah dalam SHR tetapi 
manfaatnya adalah terhad dan sementara sahaja. Kajian ini memeriksa kesan 
peliharaan silang, pemberian melatonin semasa antenatal dan postnatal atau 
kombinasi kedua-duanya ke atas perkembangan hipertensi dan sistem 
antioksidan/oksidan ginjal dalam tikus SHR dan WKY.  Pada peringkat pertama 
kajian, tekanan darah dan profil antioksidan diukur dalam tikus SHR dan WKY. 
Seterusnya, kesan peliharaan silang diperiksa apabila anak tikus SHR dan WKY 
berusia satu hari dipelihara silang oleh ibu tikus yang berlawanan strain dan anak 
tikus jantan dipelihara sehingga berusia 16 minggu.  Pada peringkat seterusnya, 
pemberian melatonin (10mg/kg berat badan/hari) melalui air minuman kepada ibu 
SHR dan WKY mulai hari pertama mengandung sehingga hari ke-21 postpartum, 
dan kemudiannya pemberian melatonin dilanjutkan kepada sebahagian daripada anak 
tikus jantan sehingga berusia 16 minggu.  Pada peringkat seterusnya, anak daripada 
ibu WKY dan SHR yang diberi melatonin dipelihara silang dari usia satu hari 
sehingga bercerai susu dan pemberian melatonin diteruskan kepada sebahagian 
daripada anak tikus jantan yang telah bercerai susu sehingga berusia 16 minggu.  
Tekanan darah sistolik (SBP) anak tikus jantan dicatat pada usia 4, 6, 8, 12 dan 16 
minggu serta tisu ginjalnya dipungut untuk menganggar status antioksidan/oksidan 
pada setiap penghujung kajian menurut kategori usia.   
 xxvii 
 Min SBP dalam SHR adalah lebih tinggi secara signifikan mulai usia 6 
minggu manakala aktiviti glutation peroksidase (GPx) dan paras protein GPx-1 
dalam SHR adalah lebih rendah secara signifikan antara usia 8 hingga 16 minggu, 
berbanding dengan WKY kawalan.  Sebaliknya, aktiviti katalase (CAT) dan paras 
proteinnya adalah lebih tinggi secara signifikan dalam SHR mulai usia 6 minggu, 
manakala mRNA CAT adalah lebih tinggi secara signifikan mulai usia 4 minggu.  
Selain daripada itu, status antioksidan keseluruhan (TAS) adalah lebih tinggi secara 
signifikan dan penanda pemperoksidaan lipid (TBARS) adalah lebih rendah secara 
signifikan dalam SHR pada usia 16 minggu.  Tahap hidrogen peroksida (H2O2) 
adalah lebih rendah secara signifikan dalam SHR pada usia 8 hingga 16 minggu.  
SBP mencatatkan penurunan secara signifikan dalam SHR yang dipelihara oleh ibu 
WKY berbanding kawalan sehingga usia 12 minggu.  TAS didapati lebih rendah 
secara signifikan dalam WKY yang diperlihara oleh ibu SHR pada usia 4 minggu, 
manakala TBARS didapati lebih rendah secara signifikan dalam SHR yang 
dipelihara oleh ibu WKY pada usia 4 minggu berbanding dengan kawalan 
berpadankan usia masing-masing.  
 Anak SHR yang menerima melatonin melalui ibu sehingga hari ke-21 
postnatal hanya mencatat penurunan SBP secara signifikan sehingga usia 8 minggu 
berbanding SHR kawalan berpadankan usia yang tidak dirawat.  Walau 
bagaimanapun, jika rawatan melatonin (melalui air minuman) diteruskan selepas 
bercerai susu, SBP dalam anak SHR menunjukkan penurunan signifikan sehingga 
usia 16 minggu. Aktiviti GPx dan glutation s-transferase (GST) dalam  SHR yang 
menerima melatonin sehingga usia 16 minggu adalah lebih tinggi secara signifikan 
pada usia 16 minggu, dan tahap glutation keseluruhan adalah lebih tinggi secara 
 xxviii 
signifikan pada usia 4, 12 dan 16 minggu berbanding dengan SHR yang tidak 
dirawat.    
 SBP adalah lebih rendah secara signifikan hanya pada usia 12 dan 16 minggu 
dalam SHR yang diperlihara oleh ibu WKY dan diberi melatonin sepanjang tempoh 
eksperimen berbanding dengan SHR yang dipelihara oleh ibu WKY dan tidak 
dirawat, tetapi SBP adalah lebih rendah secara signifikan sepanjang tempoh 
eksperimen dalam SHR yang tidak dirawat sama ada dipelihara oleh ibu SHR atau 
WKY.  Aktiviti GPx dan GST mencatatkan peningkatan signifikan dalam SHR yang 
dipelihara oleh WKY dan diberi melatonin pada usia 16 minggu jika dibandingkan 
dengan SHR yang tidak dirawat sama ada dipelihara oleh ibu SHR atau WKY. 
 Sebagai kesimpulan, kajian ini mencadangkan keabnormalan major dalam 
sistem pertahanan antioksidan ginjal dalam SHR, khususnya aktiviti CAT dan GPx. 
Pemberian melatonin sama ada semasa tempoh antenatal atau postnatal, dan 
peliharaan silang dapat menurunkan kadar kenaikan SBP tetapi kesannya bersifat 
sementara dan memerlukan pemberian melatonin secara berterusan.  Pemberian 
melatonin juga telah memperbaiki sistem glutation dalam SHR. Walau 
bagaimanapun, kombinasi pemberian melatonin dan peliharaan silang tidak 
menunjukkan sebarang kesan tambahan terhadap penurunan tekanan darah jika 
dibandingkan dengan pemberian melatonin atau peliharaan silang secara berasingan.  
Walaupun keabnormalan dalam katalase berlaku sebelum kenaikan sebenar SBP 
dalam SHR, ia tidak mungkin dikaitkan secara langsung dengan patogenesis tekanan 
darah tinggi dalam strain ini pada peringkat ini. 
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EFFECTS OF CROSS-FOSTERING AND MELATONIN 
SUPPLEMENTATION ON THE DEVELOPMENT OF HYPERTENSION 
AND RENAL ANTIOXIDANT/OXIDANT SYSTEM IN 
 SPONTANEOUSLY HYPERTENSIVE RATS 
 
ABSTRACT 
  
  Various interventions in early life in SHR have been attempted to re-
programme the raised blood pressure profile in SHR but with limited and only 
transient benefits.  This study examined the effects of either cross-fostering or 
antenatal and postnatal melatonin supplementation alone or in combination on the 
development of hypertension and renal antioxidant/oxidant system in SHR and WKY 
rats.   In the first stage of the study, blood pressure and antioxidant profiles in SHR 
and WKY rats were measured.   After this the effect of cross-fostering was examined 
where one-day-old SHR and WKY pups were cross-fostered to the dam of the 
opposite strain and the male offspring were then raised up to 16 weeks of age.   In the 
next stage, melatonin (10mg/kg body weight/day) was supplemented via drinking 
water to pregnant SHR/WKY from pregnancy day-1 and up to postpartum day-21, 
and then continued to be given to some of the weaned male offspring up to 16 weeks 
of age.   In the following stage, one-day-old offspring of melatonin supplemented 
SHR and WKY dams were cross-fostered and after weaning some of these cross-
fostered male offspring continued to receive melatonin via drinking water up to 16 
weeks of age.   Systolic blood pressure (SBP) of all the male offspring was recorded 
at the age of 4, 6, 8, 12 and 16 weeks, and the kidneys were collected for the 
estimation of antioxidant/oxidant status at the end of each age category. 
 Compared to WKY controls, mean SBP in non-supplemented SHR was 
significantly higher from the age of 6 weeks onwards; glutathione peroxidase (GPx) 
activity and GPx-1 protein level was significantly lower in SHR aged 8 to 16 weeks.   
 xxx 
In contrast, significantly higher catalase (CAT) activity and its protein level was 
found in SHR aged 6 weeks and onwards, whereas elevated CAT mRNA was found 
from as early as 4 weeks of age in SHR.  In addition, significantly higher total 
antioxidant status (TAS) and lower lipid peroxidation marker (TBARS) was found in 
SHR aged 16 weeks.   The level of hydrogen peroxide (H2O2) was significantly 
lower in SHR aged 8 to 16 weeks.  In cross-fostered SHR, SBP was significantly 
lower than that in SHR controls till the age of 12 weeks.   TAS was lower in cross-
fostered WKY rats aged 4 weeks whereas TBARS was lower in cross-fostered SHR 
at 4 weeks of age when compared to their respective age-matched controls.    
 When compared to age-matched untreated SHR, SBP in SHR offspring that 
received maternal melatonin up to postnatal day-21, was significantly lower up to 8 
weeks of age only.  However, SBP in SHR offspring that continued receiving 
melatonin (via drinking water) after weaning remained significantly lower till the age 
of 16 weeks.  GPx and GST activities were significantly higher at the age of 16 
weeks, and total glutathione level was significantly higher at 4, 12 and 16 weeks in 
SHR receiving melatonin till the age of 16 weeks when compared to untreated SHR.    
 In melatonin supplemented cross-fostered SHR, SBP was significantly lower 
at the age of 12 and 16 weeks when compared to untreated cross-fostered SHR, but 
was significantly lower throughout the experimental period when compared to 
untreated or in-fostered SHR.   Activities of GPx and GST were higher in melatonin-
treated cross-fostered SHR aged 16 weeks, when compared to age-matched in-
fostered SHR and non-melatonin supplemented cross-fostered SHR.    
 In conclusion, this study suggests the presence of a major abnormality in the 
renal antioxidant defence system in SHR, particularly in CAT and GPx activities, 
Melatonin supplementation whether antenatal or postnatal and cross-fostering reduce 
 xxxi 
the rate of rise in SBP but the effect is transient and requires a continuous 
administration of melatonin.  Melatonin supplementation also improves the 
glutathione system in SHR.   A combination of melatonin supplementation and cross-
fostering however did not confer any additional impact on the blood pressure 
lowering effect of either melatonin or cross-fostering alone. The precise mechanism 
by which these two maneuvers delayed the rise in blood pressure remains unclear.  
Although the abnormality in catalase was present before the actual rise in SBP in the 
SHR, it is however not possible to directly link this abnormality to the pathogenesis 
of high blood pressure in this strain at this stage.  
 
 
 
 
 
 
 
 
 1 
CHAPTER 1                                                                                                    
GENERAL INTRODUCTION 
 
 
1.1 BACKGROUND OF THE STUDY 
 
Hypertension is a major risk factor contributing to cardiovascular, 
cerebrovascular and renal diseases, which together contribute to the high mortality 
rate worldwide.  It is estimated that there are 4.8 million individuals with 
hypertension in Malaysia (Ministry of Health Malaysia, 2008).  The third National 
Health and Morbidity Survey document indicates a prevalence of hypertension 
among adults aged 30 years and above as 42%.  From the survey it is alarming to 
note that close to two thirds of individuals with hypertension in Malaysia were 
unaware that they were hypertensive and therefore remained undiagnosed (Ministry 
of Health Malaysia, 2008).  Hypertension is often referred to as a silent killer as it 
remains symptomless and is often only detected co-incidentally or during a routine 
medical examination.  It is therefore important that hypertension is diagnosed early 
and well managed as its early and proper management has been shown to 
significantly reduce complications like strokes, myocardial infarction, congestive 
heart failure and end-stage renal disease (Collins and MacMahon, 1994; Arguedas et 
al., 2009; de Lusignan et al., 2009; Stenvinkel, 2010). 
 The public impact and economic burden of hypertension extends far beyond 
that related to the treatment of high blood pressure.  For example, in Malaysia, 
according to the Ministry of Health records, about RM145 million was spent on 
antihypertensive medicines alone in the year 2004 (Ministry of Health Malaysia, 
2008).  This estimation, however, does not include the additional costs that arise 
from the management of complications associated with hypertension like heart 
 2 
failure, myocardial infarction and renal failure and even the loss of working hours etc 
(Sarojini and Lim, 2004; Ministry of Health Malaysia, 2008).   
 Hypertension is generally classified as either primary or secondary 
hypertension.  The etiology and pathogenesis of primary or essential hypertension 
remain unidentified and under intense study.  Essential, primary, or idiopathic 
hypertension is defined as high blood pressure in which secondary causes such as 
renovascular disease, renal failure, pheochromocytoma, aldosteronism, or other 
causes of secondary hypertension are not present (Carretero and Oparil, 2000).  On 
this basis essential hypertension accounts for 95% of all cases of hypertension 
(Carretero and Oparil, 2000).  It is considered a heterogeneous disorder, with 
different patients having different causal factors that lead to high blood pressure.  
Although the causes of essential hypertension remain largely unknown, some 
information is available indicating the role of some genetic variations and 
intermediary phenotypes that might cause or be responsible for the high blood 
pressure.  Existing evidence suggests that the genetic contribution to blood pressure 
variation is about 30% (Hong et al., 1994; Marteau et al., 2005), with the rest coming 
from a number of environmental factors that have also been linked to raised blood 
pressure, including obesity, insulin resistance, high salt intake,  high alcohol intake, 
stress, aging, sedentary lifestyle, low potassium and low calcium intake (Hashimoto 
et al., 1989; Sever and Poulter, 1989; Elliott et al., 1990; Andrade et al., 2010; Fujita 
and Takei, 2010).   
 An imbalance in the antioxidant/oxidant status especially in the kidney has 
been proposed as an important pathogenic mechanism in hypertension as well as the 
progression of kidney disease (Wilcox, 2005; Nistala et al., 2008).  In addition to this, 
maternal influence during early life has also been proposed and might be one of the 
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risk factors contributing to the adult hypertension (Blizard and Adams, 1992; Ashton, 
2000; Davidge et al., 2008).  In this regard, several experimental hypertension 
models e.g. spontaneously hypertensive rats, Dahl’s, Milan, Lyon, 
deoxycorticosterone acetate-salt hypertensive, Sabra and New Zealand strains, 
differing in the contribution of genetic and environmental factors to the raised blood 
pressure, have been developed in attempts to understand the pathogenesis of 
hypertension (Okamoto and Aoki, 1963; Kihara et al., 1993; Johns et al., 1996).  The 
spontaneously hypertensive rat (SHR), the closest animal model that represents 
human essential hypertension, and its Wistar-Kyoto (WKY) normotensive control 
were developed in 1963 by Okamoto and Aoki in Japan (Okamoto and Aoki, 1963).  
SHR exhibits spontaneous hypertension with many features in common with human 
essential hypertension, which include elevated peripheral resistance, increased 
cardiac output, elevated sympathetic nervous activity and cardiovascular hypertrophy 
(Frohlich, 1986; Zicha and Kunes, 1999; Girouard et al., 2004).  Furthermore, as in 
human, its blood pressure is readily lowered with peripheral vasodilators, calcium 
channel antagonists and blockers of the renin-angiotensin system (Zicha and Kunes, 
1999; Polizio and Pena, 2005; Liskova et al., 2010).  Numerous sophisticated 
attempts have been made to modify the natural course of hypertension in adult SHR 
with established hypertension via various pharmacological and nutritional 
interventions (Zicha and Kunes, 1999; Nava et al., 2003; Rodriguez-Iturbe et al., 
2003; Khanna et al., 2008; Nuyt and Alexander, 2009).  In contrast, relatively little 
attention has been devoted to studies involving pre-weaning or young SHR in a bid 
to prevent the rise in blood pressure.  Modification of pre-weaning maternal 
environment through cross-fostering of one-day-old SHR offspring to normotensive 
dams e.g have shown that cross-fostering significantly delayed the development of 
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high blood pressure in these SHR offspring (Cierpial and McCarty, 1987a; McCarty 
and Tong, 1995; Di Nicolantonio et al., 2006).  Although the precise reason for this 
delay in the rise in blood pressure was not evident, it was however attributed to 
differences in quality and quantity of milk delivered to the offspring and perhaps due 
to exposure of the SHR offspring to a different pattern of maternal behaviour 
(McCarty and Tong, 1995; Gouldsborough et al., 1998).  Whilst the impact of cross-
fostering is only temporary, its influence nevertheless needs to be examined further 
to identify the factor responsible for the hypotensive effect and possibly also the 
mechanism by which the blood pressure is lowered.  In this regard, the effect of 
cross-fostering on the renal antioxidant/oxidant status in SHR has not been 
investigated thoroughly and efforts could be made to examine the mechanism and 
possibly also identify the particular factor in renal antioxidant/oxidant system. 
 A number of reports over the years have documented a possible link between 
melatonin and the pathogenesis of hypertension.  Decreased melatonin levels have 
been reported in hypertension (Jonas et al., 2003; Leibowitz et al., 2008), and 
melatonin supplementation has been shown to successfully ameliorate or reduce the 
high blood pressure in humans as well as in experimental animal models  (Cagnacci 
et al., 2005; Pechanova et al., 2007).  Clinical utility of melatonin in antenatal, 
parturition and postnatal life has been claimed to result in a wide range of health 
benefits, improved quality of life and reduction of complications during the neonatal 
period (Gitto et al., 2009).  Maternal melatonin treatment has been reported to reduce 
the raised blood pressure in offspring of genetically hypertensive animals (Kim et al., 
2002).  Nevertheless, the association between its hypotensive and antioxidative 
effects and the regulation of renal antioxidant/oxidant system remains uncertain, 
particularly when administered during the antenatal, perinatal and postpartum 
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periods.  This study attempts to examine the impact of melatonin supplementation 
and cross-fostering either alone or in combination on the development of high blood 
pressure and renal antioxidant system in SHR.  
The following literature review focuses on the basic concept of oxidative 
stress and their harmful effects on cells and tissues; and also the protective role of 
the antioxidant defence system including antioxidant properties of melatonin in the 
maintenance of homeostasis of the oxidant and antioxidant status in mammals.  In 
addition, the role of oxidative stress, maternal and environmental factors in the 
development of hypertension are also reviewed.   
 
1.2 REVIEW OF LITERATURE 
 
1.2.1 Concept of oxidative stress 
 
Metabolism of oxygen by cells generates potentially deleterious reactive 
oxygen species (ROS).  During mitochondrial respiration, electron transport involves 
a coordinated four electron reduction of oxygen to water in the electron transport 
chain.  However a small number of electrons “leak” prematurely from the 
mitochondrial respiratory chain enzymes forming the oxygen free radical i.e 
superoxide anion (Cadenas and Davies, 2000).  Measurements of sub-mitochondrial 
particles suggest a leak of 1-3% of all electrons in the transport chain that go on to 
generate the superoxide radical (Cadenas and Davies, 2000).  Other than 
mitochondrial electron leak, ROS is also generated by several other mechanism, 
involving the endogenous respiratory burst, enzyme reactions (especially xanthine 
oxidase, lipo-oxygenase, prostaglandin synthetase, NADPH oxidase), auto-oxidation 
reactions, and environmental stress factors like e.g. exposure to pollutants, ultraviolet 
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light, ionizing radiation, xenobiotics etc (Karbownik and Reiter, 2000; Young and 
Woodside, 2001). 
In a healthy state, there exists a dynamic balance between ROS production 
and the activity of the antioxidant defence system, which prevents the potential 
deleterious consequences of ROS.  In certain pathogenic situations, however, 
oxidative stress results when there is an imbalance between the antioxidant activity 
and ROS production.  Oxidative stress occurs when there is an excessive production 
or diminished detoxification of ROS.  Prolonged high-grade oxidative stress leads to 
tissue damage and is believed to underlie the pathogenesis of  a number of diseases 
(Gutteridge and Halliwell, 1994). 
 
1.2.2 Formation of free radicals and reactive oxygen species  
 
Atoms and molecules are most stable in the ground state when every electron 
in the valence shell has a complimentary electron that spins in the opposite direction.  
A free radical is an atom or molecule with at least one unpaired electron in the 
outermost shell, and is capable of independent existence (Halliwell and Gutteridge, 
1984; Fang et al., 2002).  The free radical nature of an atom or molecule is usually 
denoted by a superscript dot (e.g.  •H, O2•- , •OH).  Free radicals of different types 
vary widely in their chemical reactivity, but in general they are more biologically 
reactive than non-radicals. 
When two free radicals meet, their unpaired electrons can join to form a pair, 
and both radicals are eliminated.  However since most molecules present in living 
organisms do not have unpaired electrons, any free radicals produced will most likely 
react with non-radicals, thereby generating new free radicals.  Hence, free radical 
reactions tend to proceed as chain reactions.  Unpaired electrons can be associated 
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with many different atoms and molecules and there are several types of radicals that 
can be produced within the body e.g. reactive nitrogen species (RNS) and ROS 
(Droge, 2002). RNS includes nitric oxide (NO or NO•), nitrogen dioxide (NO2•), 
peroxynitrite (ONOO−), peroxynitrous acid (ONOOH), alkyl peroxynitrite (ROONO) 
and s-nitrosothiols (RSNO). ROS includes oxygen ions, free radicals and peroxides 
both inorganic and organic, which includes superoxide anion (O2•-), hydroxyl radical 
(•OH), hydrogen peroxide (H2O2), hydroperoxyl radical (HO2•), peroxyl radical 
(RO2•), alkoxyl radical (RO•), hypochlorite (HOCl−) and hypochlorus acid (HOCl) 
(Halliwell and Gutteridge, 1984; Gilbert, 2000).  These ROS are generated as 
intermediate products in the reduction of oxygen to water.  They are generally very 
small molecules and are highly reactive due to the presence of unpaired valence shell 
electron (Halliwell and Gutteridge, 1984; Gilbert, 2000).  The most important free 
radicals in many disease states are oxygen derivatives, particularly superoxide and 
the hydroxyl radical.  Superoxide radical (O2•-) is produced by the addition of a 
single electron to oxygen, and several mechanisms exist by which O2•- can be 
produced in vivo (Halliwell and Gutteridge, 1992).  Adrenaline, flavine nucleotides, 
thiol compounds, and glucose, can oxidize in the presence of oxygen to produce O2•-, 
and these reactions are greatly accelerated by the presence of transition metals such 
as iron or copper.  The electron transport chain in the inner mitochondrial membrane 
performs the reduction of oxygen to water.  During this process free radical 
intermediates are generated, which are generally tightly bound to the components of 
the transport chain.  However, there is a constant leak of a few electrons into the 
mitochondrial matrix and this results in the formation of O2•- (Becker et al., 1999).  
There might also be continuous production of O2•- by vascular endothelium to 
neutralize nitric oxide (Souchard et al., 1998), production of O2•- by other cells to 
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regulate cell growth and differentiation (Masters, 1996), and the production of O2•- 
by phagocytes during the respiratory burst (Curnutte and Babior, 1987). 
Any biological system generating O2•- will also produce hydrogen peroxide 
(H2O2) as a result of a spontaneous dismutation reaction.  In addition, several 
enzymatic reactions, including those catalyzed by glycolate oxidase and D-amino 
acid oxidase, might also produce H2O2 directly (Chance et al., 1979; Schroder and 
Eaton, 2008).  H2O2 is not a free radical itself, but is usually included under the 
general heading of ROS because it is a weak oxidizing agent that directly damages 
proteins and enzymes containing reactive thiol groups.  However, its most vital 
property is its ability to cross cell membranes freely, which O2•- generally cannot do 
(Halliwell and Gutteridge, 1990; Schroder and Eaton, 2008).  Therefore, H2O2 
formed in one location might diffuse a considerable distance before decomposing to 
yield the highly reactive hydroxyl radical, which is likely to mediate most of the 
toxic effects ascribed to H2O2.  Therefore, H2O2 acts as an agent to transmit free 
radical induced damage across cell compartments and between cells.  In the presence 
of H2O2, myeloperoxidase will generate hypochlorous acid and singlet oxygen, a 
reaction that plays an important role in the killing of bacteria by phagocytes 
(Tatsuzawa et al., 1999).   
The hydroxyl radical (•OH), or a closely related species, is probably the final 
mediator of most free radical induced tissue damage (Lloyd et al., 1997).  O2•- and 
H2O2 exert most of their pathological effects by giving rise to •OH formation.  The 
reason for this is that •OH reacts, with extremely high rate constants, with almost 
every type of molecule found in living cells including carbohydrates, amino acids, 
lipids, and nucleotides.  Although •OH formation can occur in several ways, by far 
the most important mechanism in vivo is likely to be the transition metal catalysed 
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decomposition of O2•- and H2O2 (Stohs and Bagchi, 1995).  The most important 
transition metals in human disease are iron and copper.  These elements play a key 
role in the production of •OH in vivo (Stohs and Bagchi, 1995).  H2O2 can react with 
iron II (or copper I) to generate the •OH (Equation 1).   
Equation 1: 
Fe2+ + H2O2  Fe3+ + •OH + OH− 
This reaction can occur in vivo, but the situation is complicated by the fact 
that O2•- (the major source of H2O2 in vivo) will normally also be present.  O2•- and 
H2O2 can react together directly to produce the •OH, but the rate constant for this 
reaction in aqueous solution is virtually zero.  However, if transition metal ions are 
present a reaction sequence is established that can proceed at a rapid rate (Equation 
2). 
Equation 2: 
Fe3+ + O2•-   Fe2+ + O2 
Fe2+ + H2O2  Fe3+ + •OH + OH− 
net result: 
O2•- + H2O2  OH− + •OH + O2 
The net result of the reaction sequence illustrated in Equation 2 is known as 
the Haber-Weiss reaction.  Although most iron and copper in the body are 
sequestered in forms that are not available to catalyze this reaction sequence, it is still 
of importance as a mechanism for the formation of the •OH in vivo.  The actual 
reactions, however, may be more complex than those described above and it is 
possible that other reactive intermediates such as the ferryl and perferryl radicals 
might also be formed (Halliwell and Gutteridge, 1995). 
The rate of generation of ROS appears to be balanced with the status of the 
antioxidant defence system under physiological conditions.  Oxidative stress occurs 
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when there is excessive production of ROS or a deficiency in the antioxidant system.  
During oxidative stress, the excess ROS might interact with a variety of 
macromolecules including lipids, proteins and nucleic acids resulting in cell 
dysfunction, and apoptosis (Valko et al., 2006).  Cytotoxic effect of excessive ROS 
has been frequently implicated in cardiovascular diseases including in the 
pathogenesis of high blood pressure and atherosclerosis (Touyz and Schiffrin, 2004; 
Ward and Croft, 2006; Paravicini and Touyz, 2008). 
 
1.2.3 Oxidative damage to lipid, protein and DNA 
 
Studies in vitro reveal that elevated ROS can be an important mediator in 
causing damage to cell structures.  The three main targets of ROS attack are lipid, 
proteins, and nuclei acids (Valko et al., 2006). 
Extensive lipid peroxidation in biological membranes causes alteration in 
fluidity, decreased membrane potential, increased permeability to hydrogen and other 
ions, and eventual rupture of the cell.  Peroxyl radicals can be rearranged via a 
cyclisation reaction to endoperoxides (precursors of malondialdehyde) with the final 
product of the peroxidation process being malondialdehyde (MDA) (Marnett, 1999).  
The major aldehyde product of lipid peroxidation other than MDA is 4-hydroxy-2-
nonenal (4-HNE).  MDA is mutagenic in bacterial and mammalian cells and 
carcinogenic in rats.  4-HNE is weakly mutagenic but appears to be the major toxic 
product of lipid peroxidation (Esterbauer et al., 1991).   
Oxidation of proteins changes their primary structure, including the overall 
charge, folding, and hydrophobicity.  Oxidation of the amino acid residues and/or 
peptide backbone of proteins results in the generation of protein carbonyl group 
(Marnett et al., 2003).  The process is initiated by hydrogen abstraction from the α-
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carbon in a peptide chain.  Oxygen molecule attacks the α-carbon-centered radical to 
form peroxide intermediates leading to rearrangement and subsequent cleavage of 
the peptide bond to form carbonyl-containing peptides (Dean et al., 1997).  It has 
been demonstrated that the side chains of all amino acid residues of proteins, in 
particular cysteine and methionine residues of proteins are susceptible to oxidation 
by the action of ROS/RNS (Stadtman, 2004).  Oxidation of cysteine residues may 
lead to the irreversible formation of mixed disulphides between protein thiol groups 
(–SH) and low molecular weight thiols, in particular GSH (S-glutathiolation).  
Oxidatively modified proteins are susceptible to increased aggregation and 
degradation (Nystrom, 2005).  Quantitative measurement of carbonyl concentration 
is a good indicator of ROS-mediated protein oxidation (Dalle-Donne et al., 2005).   
ROS-induced damage of DNA include changes in both DNA structure and 
chemistry, with the result being strand breakage leading to gene mutations in the 
event a cell is rendered incapable of DNA repair, or there is miscoding caused by the 
repair process (Schnackenberg, 2002).  The hydroxyl radical is known to react with 
all components of the DNA molecule, damaging both the purine and pyrimidine 
bases and also the deoxyribose backbone (Halliwell, 1991).  The most extensively 
studied DNA lesion is the formation of 8-OHdG, which is derived from hydroxyl 
attack on deoxyguanosine (Shigenaga and Ames, 1991).  Irreversible modification of 
genetic material resulting from these “oxidative damage” incidents represents the 
first step in mutagenesis, carcinogenesis, and ageing (Valko et al., 2007). 
Whether ROS attacks these targets significantly depends upon the delicate 
balance between the levels of ROS and antioxidants.  Under many conditions, an 
increase in ROS formation also concurrently signals the activation of antioxidant 
enzymes to aid in the increased metabolism necessary to achieve redox balance.  
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However, when the amount of ROS produced exceeds the capabilities of the 
antioxidants, oxidative stress results (Halliwell and Gutteridge, 1984; Young and 
Woodside, 2001).  Cells are normally able to defend themselves against ROS 
damage through the concurrent existence of the antioxidant defence systems in the 
cell. 
 
1.2.4  Antioxidant defence systems 
 
The antioxidant system of the cell can be divided into two major groups: 
enzymatic antioxidants (e.g., superoxide dismutase, catalase, glutathione peroxidase, 
glutathione reductase and glutathione S-transferase) and non-enzymatic antioxidant 
including chain breaking antioxidants (e.g., glutathione, melatonin, vitamin E and C) 
and transition metal binding proteins (e.g., ferritin, transferrin, lactoferrin, and 
caeruloplasmin).  The first line of antioxidant defence in cell is provided by the 
antioxidant enzymes (Gutteridge and Halliwell, 1994). 
 
1.2.4 (a) Enzymatic antioxidants 
 
Primary enzymatic antioxidants include superoxide dismutase, catalase and 
glutathione peroxidase (Chance et al., 1979).  A number of enzymes are involved in 
the supply of substrates and reducing power e.g.NADPH for primary antioxidants 
such as glutathione reductase and glucose-6-phosphate dehydrogenase, but they do 
not directly remove ROS.  Glutathione S-transferase conjugates reduced glutathione 
with xenobiotics and toxins that can potentially generate ROS.   
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(i) Superoxide dismutase 
 Superoxide dismutase (SOD) protects oxygen-metabolizing cells against 
harmful effects of superoxide free-radical, O2•-.  SOD catalyses the dismutation of 
superoxide to hydrogen peroxide and oxygen (Equation 3) (Gutteridge and Halliwell, 
1994). 
Equation 3: 
2 O2•-+ 2H+ H2O2 + O2 
SOD, however must work in conjunction with other enzymes that help 
decompose H2O2  like e.g. catalase and glutathione peroxidase.   If left unchallenged, 
H2O2  could migrate from its site of formation and form the very reactive ·OH   when 
it comes in contact with iron or copper ions.  H2O2 also possesses a serious threat to 
copper-zinc containing SOD and glutathione peroxidase itself as it inactivates these 
enzymes (Gutteridge and Halliwell, 1994). 
In humans, three isoforms of SOD have been described, each with a specific 
subcellular location and different tissue distribution: (1) copper-zinc containing SOD 
(Cu/Zn-SOD) is preponderant in the cytoplasm, nucleus, and peroxisomes (2), 
manganese-containing SOD (Mn-SOD) present in the mitochondria and a small 
fraction in the cytosol, and (3) extracellular copper-zinc containing SOD (EC-SOD).   
Cu/Zn-SOD is principally found in the cytosol and peroxisomes.  It is 
composed of two identical subunits of 32.5kDa in which each subunit contains one 
copper and one zinc ion bridged by a histamine residue at its active site (McCord and 
Fridovich, 1969).  It deals with O2•- produced by cytosolic oxidases and from the 
cytochrome P450 enzymes, which are located in the endoplasmic reticulum of the 
cell.  Cu/Zn-SOD contributes the most to the total SOD activity.  It is believed to 
play a major role in the first line of antioxidant defence system (Marklund, 1982).   
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Mn-SOD is found in the mitochondria of almost all cells.  It is a 
homotetramer containing one manganese ion per subunit with a molecular weight of 
96kDa.  Mn-SOD, presumably removes O2•-  produced as a result of electron leakage 
to O2 from the mitochondrial electron transport chain and by mitochondria oxidase 
enzymes (Fridovich, 1982).  Mn-SOD has been shown to be greatly induced and 
depressed by cytokines, but is only moderately influenced by oxidants in human 
fibroblasts.  Cu/Zn-SOD and Mn-SOD are readily distinguished, even in crude 
extract, since the former is inhibited by cyanide and is stable to treatment by a 
mixture of chloroform and ethanol, whereas the latter is resistant to cyanide but is 
denatured by chloroform and ethanol (Gutteridge and Halliwell, 1994; Stralin and 
Marklund, 1994). 
EC-SOD is a secretory copper and zinc containing SOD which is the major 
SOD detectable in cellular fluids (McIntyre et al., 1999).  It is synthesized by only a 
few cell types, including fibroblasts and endothelial cells.  EC-SOD has a molecular 
weight of 130kDa.  It is a homotetramer in which each subunit contains one copper 
and one zinc ion.  EC-SOD is believed to play a role in the regulation of vascular 
tone, because endothelial derived relaxing factor e.g.  nitric oxide is neutralized in 
the plasma by superoxide (McIntyre et al., 1999).   
Unlike most enzymes, SOD lacks Michaelis constant (Km), and its catalytic 
activity increases with increasing O2•- concentration (Chance et al., 1979).  Hence, 
assays of SOD activity are usually based on indirect method that involves inhibiting 
reaction in which O2•- is generated (Fridovich, 1982).  Therefore, it is not always 
meaningful to compare reported SOD activities between studies that use different 
assay methods.   
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(ii) Catalase 
 
Catalase, (CAT) is a tetrameric enzyme with a molecular weight of 240kDa.  
Each identical subunit of 60kDa contains a haem group and a molecule of NADPH 
(Kirkman et al., 1987).  It is largely located within cells in peroxisomes, which also 
contain most of the enzymes capable of generating H2O2 (Schrader and Fahimi, 
2006).  The amount of CAT in the cytoplasm and other subcellular compartments 
remains unclear, because peroxisomes are easily ruptured during manipulation of 
cells.  It is well distributed in all the cells but the greatest activity is believed to be 
present in hepatocytes and erythrocytes.  Although it has a very large capacity to 
destroy H2O2, its affinity for H2O2 is low.  It catalyses the two stage conversion of 
H2O2 to water and oxygen in the presence of iron as a cofactor (Equation 4 & 5). 
Equation 4 & 5: 
CAT –Fe (III) + H2O2 compound I 
compound I + H2O2  CAT –Fe(III) + 2 H2O + O2 
The rate constant for the reactions described above is extremely high (~107 
M/sec), implying that it is virtually impossible to saturate the enzyme in vivo.  CAT 
can also oxidize different toxins, such as formaldehyde, formic acid, phenols, and 
alcohols.  In doing so, it uses hydrogen peroxide (Mates et al., 1999) according to the 
reaction as stated in Equation 6.   
Equation 6: 
H2O2 + H2R 2 H2O + R 
Azide and cyanide are both inhibitors of catalase, an inhibition often used to 
partition CAT activity from glutathione peroxidase activity in enzymes assays in 
crude tissue extracts.  Caution should be taken with the reported CAT activity, 
because it is determined not only by the enzyme protein present in the assay medium 
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but also by the concentration of H2O2 used.  Therefore, it is not always meaningful to 
compare reported CAT activities between studies that use different concentration of 
H2O2 (Gutteridge and Halliwell, 1994). 
 
(iii) Glutathione peroxidase  
 
Glutathione peroxidase, GPx catalyzes the reduction of H2O2 to H2O utilizing 
the reducing equivalents from reduced glutathione (GSH) in which GSH is oxidized 
to oxidized glutathione, GSSG (Equation 7).  In addition, other peroxides including 
lipid hydroperoxides, can also act as substrates for GPx, which might therefore play a 
role in repairing damage resulting from lipid peroxidation (Equation 8) (Forstrom et 
al., 1978). 
Equation 7: 
H2O2 + 2GSHGSSG + 2 H2O 
Equation 8: 
ROOH + 2GSHGSSG + H2O + ROH 
 GPx is a homotetramer with each 22kDa subunit bound to a selenium atom 
existing as a selenocysteine (Forstrom et al., 1978).   It requires selenium at the 
active site for its catalytic function, and deficiency of this enzyme might occur in the 
presence of severe selenium deficiency (Nakane et al., 1998).   There are six 
isoforms of GPx protein that have been identified to date, which are referred to as 
GPx-1 to GPx-6.  Data from activity assays in vitro suggest that all the six isoforms 
use GSH to catalyze the reduction of H2O2 and lipid peroxides.  GPx-1 is the most 
abundant selenoperoxidase and is ubiquitously expressed in almost all tissues (Flohe 
et al., 1973; Rotruck et al., 1973).  GPx-2 expression is most prominent in the 
gastrointestinal tract (Chu et al., 1997).  Expression of GPx-3 is greatest in the 
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kidney, although this enzyme is also expressed in various other tissues and is 
secreted into extracellular fluid as a glycoprotein (Takakhashi et al., 1987; 
Yoshimura et al., 1991).  Different from other glutathione peroxidases, GPx-4 or 
phospholipid hydroperoxide is not a tetramer but rather a monomer, and is the only 
GPx enzyme that reduces phospholipid hydroperoxides (Thomas et al., 1990).  
Recently, GPx-6 was identified as a selenoprotein in the human genome by 
homology search (Kryukov et al., 2003).  However, GPx-6 from rodents and GPx-5 
from both humans and rodents do not contain selenocysteine or selenium (Kryukov 
et al., 2003).   
The activity of GPx is dependent on the constant availability of GSH (Holben 
and Smith, 1999).  The ratio of GSH to GSSG is usually kept very high (more than 
99:1) as a result of the activity of the enzyme glutathione reductase.  The NADPH 
required by this enzyme to restore the supply of GSH is provided by the pentose 
phosphate pathway.  Any competing pathway that utilizes NADPH (such as the 
aldose reductase pathway) might lead to a deficiency of GSH and hence impair the 
action of GPx (Meister, 1981). 
 There is a substrate overlap between GPx and CAT.  GPx has a much greater 
affinity for H2O2 at low concentrations, and CAT, with its low affinity is usually 
recruited at high concentrations.  The Km of CAT (up to 25mM) is >4000-fold higher 
than the Km of GPx (6µM) (Carmagnol et al., 1983; Mozaffar et al., 1986).  This 
means at low steady state substrate concentrations, GPx plays a more prominent role 
in removing H2O2, and at high substrate concentrations, CAT plays a greater 
effective role in removing H2O2.  Therefore, GPx is thought to be a major defence 
mechanism in low level of oxidative stress and CAT is effective in high level of 
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oxidative stress or in the case of limited GPx reaction in protecting cells from H2O2  
(Wassmann et al., 2004) 
 
(iv) Glutathione reductase 
Glutathione reductase, GR is a dimer consisting of two identical subunits of 
molecular mass 50kDa each, and possesses one flavin molecule at its active site.  It is 
an enzyme that reduces glutathione disulfide (GSSG) to the sulfhydryl form, GSH.  
GR catalyzes the reduction of one mole of GSSG into two moles of GSH in the 
presence of one mole of NADPH as electron donor (Fridovich, 1978) (Equation 9).  
The required NADPH is usually formed by the pentose phosphate pathway (Champe, 
2008).  GR is essential for the GSH redox cycle, which maintains adequate levels of 
cellular GSH.  A high GSH/GSSG ratio is essential for protection against oxidative 
stress. 
Equation 9: 
GSSG + NADPH + H+   2GSH + NADP+ 
 
(v) Glutathione S-transferase 
 
Glutathione S-transferase, GST is an important part of the cellular 
detoxification system and protects cells against reactive oxygen metabolites.  GST 
protects cells against electrophiles and xenobiotics by conjugating them to 
glutathione, thereby neutralizing their electrophilic sites, and rendering the products 
more water soluble.  The glutathione conjugates are metabolized further to 
mercapuric acid and then excreted (Boyland and Chasseaud, 1969).   
All eukaryotic species possess multiple cytosolic and membrane-bound GST 
isoenzymes (microsomal GST and leukotriene C4 synthetase), each of which 
